Expert Insight Into:
Sublobar Resection for Patients with Peripheral Small Adenocarcinomas of the Lung: Surgical Outcome is Associated with Features on Computed Tomographic Imaging
Medical Writer: Karen Gravelle, PhD
Expert Faculty: Dr. Joseph B. Shrager, MD
Medical Writer: Karen Gravelle, PhD
Expert Faculty: Dr. Joseph B. Shrager, MD
Click here to view our current activities in Oncology.
This article review discusses the use of tumor shadow disappearance rate (TDR) on high-resolution computed tomography to identify early small adenocarcinomas of the lung suitable for limited pulmonary resection. Dr. Shrager comments on this retrospective study and its implications for treatment. This article review is part of the Advanced Certificate Program: Lung Cancer Management II.
Joseph B. Shrager, MD
- Professor and Chief, Division of Thoracic Surgery
- Cardiothoracic Surgery
- Stanford University Medical Center/School of Medicine
- Stanford, CA
Ramaswamy Govindan, MD, is on the speakers bureau of Eli Lilly and Company and Genentech, Inc; and is on the advisory board of AstraZeneca and Pfizer, Inc.
Roy S. Herbst, MD, PhD, has received grant/research support from Amgen Inc, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc, and Sanofi-Aventis; is a consultant for Amgen Inc, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, and Genentech, Inc, ImClone Systems, Pfizer and Company, and Sanofi-Aventis; and is on the speakers bureau of Eli Lilly and Company and Genentech, Inc.
Corey J. Langer, MD, FACP, is a consultant for and is on the speakers bureau of Genentech, Inc and OSI Pharmaceuticals, Inc.
Joseph B. Shrager, MD, has no real or apparent conflicts of interest to report.
Michael Unger, MD, FACP, FCCP, has disclosed no significant relationships.
Available for CME/CE:
Physicians
Publish Date: Dec 12, 2008 Termination Date: Dec 12, 2009Nurses
Publish Date: Dec 12, 2008 Termination Date: Dec 12, 2009Pharmacists
Publish Date: Dec 12, 2008 Termination Date: Dec 12, 2009Estimated time for completion of this activity:
CNE: 30.00 minutes
CPE: 1.0 hour
Target Audience
This series of activities is designed for oncologists and other clinicians who specialize in and care for patients with lung cancer.
Activity Goal
The goal of these CME/CE activities is to examine current and emerging strategies for treating and managing patients with lung cancer.
Learning Objective (s)
- Integrate knowledge of current and emerging strategies in screening, diagnosis, and treatment options into clinical practice, to improve the outcomes of patients with lung cancer.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
EduPro Resources LLC is an approved provider of continuing nursing education by NJSNA, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Provider Number P208-8/08-11.
EduPro Resources LLC is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-14387.
This activity is accredited for 0.50 contact hours.
Disclaimer
Accreditation refers to educational content only and does not imply endorsement of products by NJSNA, ANCC, CBRN, or EduPro Resources LLC.
Co-Provider Statement
This activity is co-provided by Projects In Knowledge and EduPro Resources LLC.
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This article review is worth up to 1.0 contact hour (0.1 CEU). The ACPE Universal Program Number assigned to this activity is 052-000-08-059-H01-P.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Joseph B. Shrager, MD has no real or apparent conflicts of interest to report.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Karen Gravelle, PhD has disclosed no significant relationships.
Off-label drug statement: NA
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Elizabeth M. Gore, MD has no real or apparent conflicts of interest to report.
Ramaswamy Govindan, MD is on the speakers bureau of Eli Lilly and Company and Genentech, Inc; and is on the advisory board of AstraZeneca and Pfizer, Inc.
Roy S. Herbst, MD, PhD has received grant/research support from Amgen Inc, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc, and Sanofi-Aventis; is a consultant for Amgen Inc, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, and Genentech, Inc, ImClone Systems, Pfizer and Company, and Sanofi-Aventis; and is on the speakers bureau of Eli Lilly and Company and Genentech, Inc.
Corey J. Langer, MD, FACP is a consultant for and is on the speakers bureau of Genentech, Inc and OSI Pharmaceuticals, Inc.
Joseph B. Shrager, MD has no real or apparent conflicts of interest to report.
Michael Unger, MD, FACP, FCCP has disclosed no significant relationships.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Pfizer
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME/CE:
Physicians
Publish Date: Dec 12, 2008 Termination Date: Dec 12, 2009Nurses
Publish Date: Dec 12, 2008 Termination Date: Dec 12, 2009Pharmacists
Publish Date: Dec 12, 2008 Termination Date: Dec 12, 2009Estimated time for completion of this activity:
CNE: 30.00 minutes
CPE: 1.0 hour
Target Audience
This series of activities is designed for oncologists and other clinicians who specialize in and care for patients with lung cancer.
Activity Goal
The goal of these CME/CE activities is to examine current and emerging strategies for treating and managing patients with lung cancer.
Learning Objective (s)
- Integrate knowledge of current and emerging strategies in screening, diagnosis, and treatment options into clinical practice, to improve the outcomes of patients with lung cancer.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
EduPro Resources LLC is an approved provider of continuing nursing education by NJSNA, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. Provider Number P208-8/08-11.
EduPro Resources LLC is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-14387.
This activity is accredited for 0.50 contact hours.
Disclaimer
Accreditation refers to educational content only and does not imply endorsement of products by NJSNA, ANCC, CBRN, or EduPro Resources LLC.
Co-Provider Statement
This activity is co-provided by Projects In Knowledge and EduPro Resources LLC.
CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This article review is worth up to 1.0 contact hour (0.1 CEU). The ACPE Universal Program Number assigned to this activity is 052-000-08-059-H01-P.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Joseph B. Shrager, MD has no real or apparent conflicts of interest to report.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Karen Gravelle, PhD has disclosed no significant relationships.
Off-label drug statement: NA
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Elizabeth M. Gore, MD has no real or apparent conflicts of interest to report.
Ramaswamy Govindan, MD is on the speakers bureau of Eli Lilly and Company and Genentech, Inc; and is on the advisory board of AstraZeneca and Pfizer, Inc.
Roy S. Herbst, MD, PhD has received grant/research support from Amgen Inc, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc, and Sanofi-Aventis; is a consultant for Amgen Inc, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, and Genentech, Inc, ImClone Systems, Pfizer and Company, and Sanofi-Aventis; and is on the speakers bureau of Eli Lilly and Company and Genentech, Inc.
Corey J. Langer, MD, FACP is a consultant for and is on the speakers bureau of Genentech, Inc and OSI Pharmaceuticals, Inc.
Joseph B. Shrager, MD has no real or apparent conflicts of interest to report.
Michael Unger, MD, FACP, FCCP has disclosed no significant relationships.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Pfizer
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
|
||||||||||||||||||||||||||||||||||||||||||||||



